A comprehensive study demonstrating that p-glycoprotein function is directly affected by changes in pH: Implications for intestinal pH and effects on drug absorption

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4258-4268

  Mitra, Pallabi ^a   Audus, Kenneth ^a   Williams, Gervan ^b   Yazdanian, Mehran ^b   Galinis, Deborah ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b CEPHALON INC   (United States)

Author keywords

ABC transporters; Absorption; Active transport; Bioavailability; Caco 2 cells; Drug transport; Efflux pumps; Gastrointestinal; Intestinal absorption; MDCK cells

Indexed keywords

ADENOSINE TRIPHOSPHATASE; COLCHICINE; DEXAMETHASONE; DIGOXIN; ETOPOSIDE; GLYCOPROTEIN P; PACLITAXEL; TESTOSTERONE; ABCB1 PROTEIN, HUMAN; ADENOSINE TRIPHOSPHATE; MULTIDRUG RESISTANCE PROTEIN;

ACIDITY; ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL PH; CELL STRAIN; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG UPTAKE; ENZYME ACTIVITY; KIDNEY CELL; NONHUMAN; PH; ANIMAL; BIOAVAILABILITY; CACO 2 CELL LINE; CHEMISTRY; DOG; GENETIC TRANSFECTION; GENETICS; HUMAN; HYDROLYSIS; INTESTINE; INTESTINE ABSORPTION; MDCK CELL LINE; METABOLISM; PERMEABILITY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; TRANSPORT AT THE CELLULAR LEVEL;

ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; COLCHICINE; DIGOXIN; DOGS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INTESTINAL ABSORPTION; INTESTINES; MADIN DARBY CANINE KIDNEY CELLS; P-GLYCOPROTEINS; PERMEABILITY; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 80052258998     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22596     Document Type: Article

References (61)

1. You G, Morris ME. 2007. Drug transporters: Molecular characterization and role in drug disposition. 1st ed. New Jersey: John Wiley & Sons, Inc.
2. Fischer V, Einolf HJ, Cohen D. 2005. Efflux transporters and their clinical relevance. Mini Rev Med Chem 5(2):183-195.
3. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim BiopHys Acta 455(1):152-162.
4. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
5. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, Goldman S. 1979. Digoxin-quinidine interaction: Pharmacokinetic evaluation. N Engl J Med 300(22):1238-1241.
6. Thyssen A, Vermeulen A, Fuseau E, Fabre MA, Mannaert E. 2010. Population Pharmacokinetics of oral risperidone in children, adolescents, and adults with psychiatric disorders. Clin Pharmacokinet 49(7):465-478.
7. Bruyere A, Decleves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, Scherrmann JM, Mouly S. Effect of variations in the amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm DOI: 10.1021/mp100015x.
8. Varma MV, Perumal OP, Panchagnula R. 2006. Functional role of P-glycoprotein in limiting peroral drug absorption: Optimizing drug delivery. Curr Opin Chem Biol 10(4):367-373.
9. Daugherty AL, Mrsny RJ. 1999. Transcellular uptake mechanisms of the intestinal epithelial barrier Part one. Pharm Sci Technol Today 4(2):144-151.
10. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y. 2009. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67(1):44-49.
11. Lahner E, Annibale B, Delle Fave G. 2009. Systematic review: Impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 29(12):1219-1229.
12. Neuhoff S, Ungell AL, Zamora I, Artursson P. 2003. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug-drug interactions. Pharm Res 20(8):1141-1148.
13. Altenberg GA, Young G, Horton JK, Glass D, Belli JA, Reuss L. 1993. Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance. Proc Natl Acad Sci U S A 90(20):9735-9738.
14. Lotz C, Kelleher DK, Gassner B, Gekle M, Vaupel P, Thews O. 2007. Role of the tumor microenvironment in the activity and expression of the P-glycoprotein in human colon carcinoma cells. Oncol Rep 17(1):239-244.
15. Thews O, Gassner B, Kelleher DK, Schwerdt G, Gekle M. 2006. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 8(2):143-152.
16. Mankhetkorn S, Garnier-Suillerot A. 1998. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. Eur J Pharmacol 343(2-3):313-321.
17. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM. 2006. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3(1):62-69.
18. Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19(6):765-772.
19. Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, Szabo K, de Haas M, van Deemter L, Borst P, Varadi A, Sarkadi B. 1998. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273(48):32167-32175.
20. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. 2000. Inhibitory effect of the reversal agents V-104, GF120918, and Pluronic L61 on MDR1 Pgp-, MRP1-, and MRP2-mediated transport. Br J Cancer 83(3):366-374.
21. Shepard RL, Cao J, Starling JJ, Dantzig AH. 2003. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103(1):121-125.
22. Tang F, Ouyang H, Yang JZ, Borchardt RT. 2004. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. J Pharm Sci 93(5):1185-1194.
23. Young AM, Audus KL, Proudfoot J, Yazdanian M. 2006. Tetrazole compounds: The effect of structure and pH on Caco-2 cell permeability. J Pharm Sci 95(4):717-725.
24. Neuhoff S, Ungell AL, Zamora I, Artursson P. 2005. pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur J Pharm Sci 25(2-3):211-220.
25. Troutman MD, Thakker DR. 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20(8):1200-1209.
26. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. 1988. Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem BiopHys 263(2):424-436.
27. Yazdanian M, Glynn SL, Wright JL, Hawi A. 1998. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15(9):1490-1494.
28. Windholz M BS, Blumetti RF, Otterbein ES. 1983. Merck Index 10th ed. New Jersey: Merck and Company, Inc.
29. Chan LM, Cooper AE, Dudley AL, Ford D, Hirst BH. 2004. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification. J Drug Target 12(7):405-413.
30. Li YH, Ito K, Tsuda Y, Kohda R, Yamada H, Itoh T. 1999. Mechanism of intestinal absorption of an orally active beta-lactam prodrug: Uptake and transport of carindacillin in Caco-2 cells. J Pharmacol Exp Ther 290(3):958-964.
31. Ambudkar SV, Kim IW, Sauna ZE. 2006. The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27(5):392-400.
32. Polli JW, Wring SA, HumpHreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299(2):620-628.
33. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. 1992. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267(7):4854-4858.
34. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, Kindmark A, Artursson P. 2006. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29(3-4):269-277.
35. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL. 2006. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: Comparison between human segments and Caco-2 cells. Eur J Pharm Sci 28(4):291-299.
36. Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH. 2004. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 311(2):476-484.
37. Xia CQ, Liu N, Yang D, Miwa G, Gan LS. 2005. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33(5):637-643.
38. Dahan A, Sabit H, Amidon GL. 2009. Multiple efflux pumps are involved in the transepithelial transport of colchicine: Combined effect of P-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 37(10):2028-2036.
39. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA. 1999. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290(2):854-862.
40. Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H, Bentz J. 2008. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metab Dispos 36(2):452-460.
41. Sauna ZE, Ambudkar SV. 2007. About a switch: How P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6(1):13-23.
42. Shapiro AB, Ling V. 1997. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250(1):130-137.
43. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. 2000. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58(3):624-632.
44. Safa AR. 2004. Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents 4(1):1-17.
45. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. 2002. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61(5):964-973.
46. Globisch C, Pajeva IK, Wiese M. 2008. Identification of putative binding sites of P-glycoprotein based on its homology model. ChemMedChem 3(2):280-295.
47. Meier M, Blatter XL, Seelig A, Seelig J. 2006. Interaction of verapamil with lipid membranes and P-glycoprotein: Connecting thermodynamics and membrane structure with functional activity. BiopHys J 91(8):2943-2955.
48. Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C. 2010. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther 48(3):192-199.
49. Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. 2009. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 14(21-22):1067-1074.
50. Cohen AF, Kroon R, Schoemaker R, Hoogkamer H, van Vliet A. 1991. Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med 115(7):540-545.
51. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. 1991. Minor effect of multiple dose omeprazole on the Pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 32(5):569-572.
52. Varma MV, Panchagnula R. 2005. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: Kinetic analysis of quinidine efflux in situ. J Pharm Sci 94(12):2632-2643.
53. Bai JP, Chang LL, Guo JH. 1996. Effects of polyacrylic polymers on the degradation of insulin and peptide drugs by chymotrypsin and trypsin. J Pharm Pharmacol 48(1):17-21.
54. Lee YH, Perry BA, Labruno S, Lee HS, Stern W, Falzone LM, Sinko PJ. 1999. Impact of regional intestinal pH modulation on absorption of peptide drugs: Oral absorption studies of salmon calcitonin in beagle dogs. Pharm Res 16(8):1233-1239.
55. Lee YH, Sinko PJ. 2000. Oral delivery of salmon calcitonin. Adv Drug Deliv Rev 42(3):225-238.
56. Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, Schellens JH. 2007. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 71(1):240-249.
57. Alfaras I, Perez M, Juan ME, Merino G, Prieto JG, Planas JM, Alvarez AI. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J Agric Food Chem 58(7):4523-4528.
58. Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y. 2007. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 35(7):1142-1148.
59. Hochman J. 2006. Role of mechanistic transport studies in lead optimization. In Optimizing the drug-like properties of leads in drug discovery; Ronald T, Borchardt EHK, Hageman MJ, Thakker DR, Stevens JL, Eds. Springer, New York, pp 26-48.
60. Ingels F, Beck B, Oth M, Augustijns P. 2004. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int J Pharm 274(1-2):221-232.
61. Deferme S, Tack J, Lammert F, Augustijns P. 2003. P-glycoprotein attenuating effect of human intestinal fluid. Pharm Res 20(6):900-903.